Cargando…
Implication of hepatokines in metabolic disorders and cardiovascular diseases
The liver is a central regulator of systemic energy homeostasis and has a pivotal role in glucose and lipid metabolism. Impaired gluconeogenesis and dyslipidemia are often observed in patients with nonalcoholic fatty liver disease (NAFLD). The liver is now recognized to be an endocrine organ that se...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816030/ https://www.ncbi.nlm.nih.gov/pubmed/27051596 http://dx.doi.org/10.1016/j.bbacli.2016.03.002 |
_version_ | 1782424655155429376 |
---|---|
author | Jung, Tae Woo Yoo, Hye Jin Choi, Kyung Mook |
author_facet | Jung, Tae Woo Yoo, Hye Jin Choi, Kyung Mook |
author_sort | Jung, Tae Woo |
collection | PubMed |
description | The liver is a central regulator of systemic energy homeostasis and has a pivotal role in glucose and lipid metabolism. Impaired gluconeogenesis and dyslipidemia are often observed in patients with nonalcoholic fatty liver disease (NAFLD). The liver is now recognized to be an endocrine organ that secretes hepatokines, which are proteins that regulate systemic metabolism and energy homeostasis. Hepatokines are known to contribute to the pathogenesis of metabolic syndrome, NAFLD, type 2 diabetes (T2DM), and cardiovascular diseases (CVDs). In this review, we focus on the roles of two major hepatokines, fetuin-A and fibroblast growth factor 21 (FGF21), as well as recently-redefined hepatokines, such as selenoprotein P, angiopoietin-like protein 4 (ANGPTL4), and leukocyte cell-derived chemotaxin 2 (LECT2). We also assess the biology and molecular mechanisms of hepatokines in the context of their potential as therapeutic targets for metabolic disorders and cardiovascular diseases. |
format | Online Article Text |
id | pubmed-4816030 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-48160302016-04-05 Implication of hepatokines in metabolic disorders and cardiovascular diseases Jung, Tae Woo Yoo, Hye Jin Choi, Kyung Mook BBA Clin Review The liver is a central regulator of systemic energy homeostasis and has a pivotal role in glucose and lipid metabolism. Impaired gluconeogenesis and dyslipidemia are often observed in patients with nonalcoholic fatty liver disease (NAFLD). The liver is now recognized to be an endocrine organ that secretes hepatokines, which are proteins that regulate systemic metabolism and energy homeostasis. Hepatokines are known to contribute to the pathogenesis of metabolic syndrome, NAFLD, type 2 diabetes (T2DM), and cardiovascular diseases (CVDs). In this review, we focus on the roles of two major hepatokines, fetuin-A and fibroblast growth factor 21 (FGF21), as well as recently-redefined hepatokines, such as selenoprotein P, angiopoietin-like protein 4 (ANGPTL4), and leukocyte cell-derived chemotaxin 2 (LECT2). We also assess the biology and molecular mechanisms of hepatokines in the context of their potential as therapeutic targets for metabolic disorders and cardiovascular diseases. Elsevier 2016-03-05 /pmc/articles/PMC4816030/ /pubmed/27051596 http://dx.doi.org/10.1016/j.bbacli.2016.03.002 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Jung, Tae Woo Yoo, Hye Jin Choi, Kyung Mook Implication of hepatokines in metabolic disorders and cardiovascular diseases |
title | Implication of hepatokines in metabolic disorders and cardiovascular diseases |
title_full | Implication of hepatokines in metabolic disorders and cardiovascular diseases |
title_fullStr | Implication of hepatokines in metabolic disorders and cardiovascular diseases |
title_full_unstemmed | Implication of hepatokines in metabolic disorders and cardiovascular diseases |
title_short | Implication of hepatokines in metabolic disorders and cardiovascular diseases |
title_sort | implication of hepatokines in metabolic disorders and cardiovascular diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816030/ https://www.ncbi.nlm.nih.gov/pubmed/27051596 http://dx.doi.org/10.1016/j.bbacli.2016.03.002 |
work_keys_str_mv | AT jungtaewoo implicationofhepatokinesinmetabolicdisordersandcardiovasculardiseases AT yoohyejin implicationofhepatokinesinmetabolicdisordersandcardiovasculardiseases AT choikyungmook implicationofhepatokinesinmetabolicdisordersandcardiovasculardiseases |